Gujarat Themis Biosyn's Q1 Financial Results Show Decline in Performance

Gujarat Themis Biosyn, a smallcap pharmaceutical company, recently announced its financial results for the quarter ending June 2024. The company's stock has been given a 'Hold' call by MarketsMOJO.

According to the financial report, Gujarat Themis Biosyn's performance has remained flat in the last quarter, with a score of -4 compared to 5 in the previous three months. This indicates a decline in the company's overall performance.

The company's Profit After Tax (PAT) for the quarter was Rs 13.24 crore, which is a decrease of 10.5% compared to the average PAT of the previous four quarters, which was Rs 14.79 crore. The near-term trend for PAT is negative.

Similarly, the company's Net Sales for the quarter were Rs 38.83 crore, a decrease of 8.5% compared to the average Net Sales of the previous four quarters, which was Rs 42.46 crore. The near-term trend for sales is also negative.

The company's Profit Before Tax less Other Income (PBT) for the quarter was Rs 17.34 crore, a decrease of 7.5% compared to the average PBT of the previous four quarters, which was Rs 18.75 crore. The near-term trend for PBT is negative.

Based on these financial results, it can be seen that Gujarat Themis Biosyn has not performed well in the last quarter. However, it is important to note that this is a fact-based analysis and does not include any external data or sources. Investors are advised to do their own research and make informed decisions.